Zhu Z et al. proposed that Anlotinib combined with metformin enhanced oxidative stress in NSCLC cells, and inhibited the mTOR pathway, demonstrating a synergistic antitumor effect [35]. Here, MTOR is linked to non-small cell lung carcinoma.